Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART19 for Very High-Risk B-ALL
NCT03792633Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2019
- Primary completion
- Apr 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of huCART-19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Pennsylvania. Started Jan 2019; status: completed.
02
Drugs
huCART-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03792633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792633.